Royce & Associates LP Arcutis Biotherapeutics, Inc. Transaction History
Royce & Associates LP
- $8.75 Billion
- Q1 2025
A detailed history of Royce & Associates LP transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Royce & Associates LP holds 267,612 shares of ARQT stock, worth $3.92 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
267,612Holding current value
$3.92 Million% of portfolio
0.05%Shares
1 transactions
Others Institutions Holding ARQT
# of Institutions
250Shares Held
126MCall Options Held
605KPut Options Held
170K-
Suvretta Capital Management, LLC New York, NY11.4MShares$167 Million7.82% of portfolio
-
Jennison Associates LLC11.4MShares$166 Million0.13% of portfolio
-
Rubric Capital Management LP New York, NY11MShares$161 Million4.91% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$129 Million8.65% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$126 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $881M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...